Summary of Sections Real Market Data in Enhanced M&A Templates at Your Fingertips Addressing the Competitive Landscape Rollout Conclusion M&A practitioners know that drafting...
LexisNexis® Practical Guidance continues to empower legal professionals with fresh, actionable insights and resources. The July 2025 update delivers a wide range of new legal tools, regulatory trackers...
LexisNexis has once again raised the bar for legal practitioners with a robust suite of new resources and tools in its Practical Guidance platform. The June 2025 updates span multiple practice areas, delivering...
Public Law No. 119-21, the One Big Beautiful Bill Act (OBBBA), represents the most comprehensive overhaul of the federal tax system since the Tax Cuts and Jobs Act of 2017 (TCJA). Enacted on July 4, 2025...
Restaurant leasing presents a unique blend of legal considerations, shaped by operational realities such as equipment needs, utility demands, and customer-facing enhancements. Review this checklist for...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
Hear expert commentary from Tom Irving and Michelle O’Brien of the Marbury Law Group on the risk generic drug companies face when utilizing a skinny label in the aftermath of the Federal Circuit’s decision in Glaxosmithkline LLC v. Teva Pharm. USA, Inc., 7 F.4th 1320 (Fed. Cir. 2021). This video discusses the evidence the court relied upon in finding induced infringement in this case and lessons for avoiding infringement.
Watch now »Related Content
Practical Guidance Updates Featuring the latest updates from your Practical Guidance account.
PRACTICAL GUIDANCE CUSTOMER EMAIL EDITION ON THE WEB
Experience results today with practical guidance, legal research, and data-driven insights—all in one place.Experience Lexis+